La Jolla Pharmaceutical Company (NASDAQ:LJPC) went up by 30.71% from its latest closing price compared to the recent 1-year high of $9.38. The company’s stock price has collected -3.43% of loss in the last five trading sessions. Press Release reported 3 hours ago that Thinking about buying stock in T2 Biosystems, Zomedica, Aldeyra Therapeutics, La Jolla Pharmaceutical, or US Well Services?
Is It Worth Investing in La Jolla Pharmaceutical Company (NASDAQ :LJPC) Right Now?
Plus, the 36-month beta value for LJPC is at 2.75. Opinions of the stock are interesting as 1 analysts out of 2 who provided ratings for La Jolla Pharmaceutical Company declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $12.00. LJPC currently public float of 26.98M and currently shorts hold a 10.85% ratio of that float. Today, the average trading volume of LJPC was 237.74K shares.
LJPC’s Market Performance
LJPC stocks went down by -3.43% for the week, with a monthly drop of -13.02% and a quarterly performance of -3.67%, while its annual performance rate touched -34.33%. The volatility ratio for the week stands at 5.38% while the volatility levels for the past 30 days are set at 5.70% for La Jolla Pharmaceutical Company. The simple moving average for the period of the last 20 days is 22.53% for LJPC stocks with a simple moving average of 7.38% for the last 200 days.
LJPC Trading at 19.10% from the 50-Day Moving Average
After a stumble in the market that brought LJPC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.10% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 5.38%, as shares surge +9.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.23% upper at present.
During the last 5 trading sessions, LJPC rose by +27.71%, which changed the moving average for the period of 200-days by +16.28% in comparison to the 20-day moving average, which settled at $4.22. In addition, La Jolla Pharmaceutical Company saw 1.55% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at LJPC starting from TANG KEVIN C, who purchase 126,665 shares at the price of $4.03 back on Sep 09. After this action, TANG KEVIN C now owns 9,405,490 shares of La Jolla Pharmaceutical Company, valued at $509,940 using the latest closing price.
RAMSAY DAVID A, the Director of La Jolla Pharmaceutical Company, purchase 1,000 shares at $3.83 during a trade that took place back on Sep 08, which means that RAMSAY DAVID A is holding 48,000 shares at $3,830 based on the most recent closing price.
Stock Fundamentals for LJPC
Current profitability levels for the company are sitting at:
- -455.02 for the present operating margin
- +64.21 for the gross margin
The net margin for La Jolla Pharmaceutical Company stands at -505.37. The total capital return value is set at -81.36, while invested capital returns managed to touch -91.34. Equity return is now at value 83.20, with -55.80 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 7.65, with the company’s debt to enterprise value settled at 0.87. The receivables turnover for the company is 10.62 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.96.